To add one more practical pearl for the PCPs in the audience: The ALT "paradox" on GLP-1 therapy: I've had several patients whose ALT transiently INCREASES in the first 2-4 weeks of GLP-1 therapy before declining. This is likely due to rapid hepatic fat mobilization causing transient lipotoxicity and hepatocyte stress. If ALT goes from 65 to 85 in the first month of semaglutide, DON'T panic and DON'T stop the drug. Check again at 6-8 weeks. In my experience, the transient rise always resolves and is followed by a sustained decline. However, if ALT rises above 3x ULN (>120 for men, >93 for women) or is accompanied by rising bilirubin, STOP the drug and refer urgently. This pattern is rare but could indicate drug-induced liver injury or unmasking of a separate hepatic pathology. Also worth noting: GLP-1 agonists can cause gallstone formation (due to rapid weight loss and bile stasis), which can present as a new ALT elevation with disproportionate ALP/GGT elevation. Always consider biliary pathology in the differential of rising liver enzymes on GLP-1 therapy.

From a pharmacy perspective, I want to flag something practical about ALT monitoring and GLP-1 prescriptions. Several of the newer GLP-1 formulations (and the MASH-specific drugs like resmetirom) have ALT monitoring built into their prescribing information: - Resmetirom (Rezdiffra): ALT and AST must be checked before starting, at months 3, 6, 9, and 12, then periodically. Drug should be discontinued if ALT > 5x ULN. - Semaglutide/tirzepatide: No mandatory liver monitoring in the PI, but it's standard of care for patients with known or suspected MASH. - Pioglitazone: ALT should be checked before starting and periodically. Don't start if ALT > 2.5x ULN. I'm seeing an increasing number of prescriptions where the prescriber checks liver enzymes at baseline but then forgets the follow-up monitoring. If you're a pharmacist reading this, consider building ALT monitoring reminders into your dispensing workflow for these medications. Also — for patients on combination therapy (GLP-1 + resmetirom + pioglitazone), the monitoring schedule gets complex. I've created a simple spreadsheet tracker I share with patients at our pharmacy. Happy to share the template if anyone wants it.

I work in clinical data analytics and wanted to add some context on why ALT thresholds matter for the conversation about GLP-1 efficacy. The traditional ALT upper limit of normal (ULN = 40 for men, 31 for women) is actually too high. Multiple large population studies have shown that optimal ALT — associated with the lowest all-cause mortality — is: - Men: < 29 U/L - Women: < 22 U/L When you recalculate ALT "normalization" rates using these stricter cutoffs, the GLP-1 numbers look different: | Drug | Traditional normalization | Optimal normalization | |------|--------------------------|----------------------| | Semaglutide 2.4mg | 51-59% | ~35-40% | | Tirzepatide 15mg | 62-74% | ~45-50% | | Survodutide 6mg | 76% | ~55-60% | This is important because a patient whose ALT goes from 75 to 38 has "normalized" by traditional standards but may still have ongoing low-grade hepatocyte injury. We should be targeting the stricter cutoffs. Also worth noting: ALT has a diurnal variation of ~10-15%. Morning fasting ALT is typically lowest. If you're tracking ALT serially, try to standardize the timing and fasting state.